Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sphinx Laboratories

Division of Eli Lilly & Co.

Latest From Sphinx Laboratories

Chemogenomics: Serendipity on a Large Scale

To eliminate a bottle neck in target validation, pharmaceutical firms are turning to a new model known as chemogenomics, the use of small molecule drugs as probes to tease out a phenotypic response from multiple poorly-understood targets. One of the most ambitious efforts to date, Amphora Discovery Corp., a spin-out of lab-on-a-chip firm Caliper Technologies, was founded in September to build a database detailing the interactions of as many as 4000-12000 biological targets with half a million compounds.
BioPharmaceutical Research and Development Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Sphinx Pharmaceutical
  • Ownership
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Eli Lilly & Co.
  • Senior Management
  • Richard W Reichow, Pres. & CEO, CFO
    Vincent Fabiano, Dir., Bus. Dev.
    John Richert, Dir., Mkt. Dev.
    Robert Pacifici, PhD, CSO
  • Contact Info
  • Sphinx Laboratories
    Phone: (919) 489-0909
    Four University Pl.
    P.O. Box 52330 Durham, NC 27707-